Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo

被引:48
作者
Ferger, B
Spratt, C
Teismann, P
Seitz, G
Kuschinsky, K
机构
[1] Univ Marburg, Fac Pharm, Inst Pharmacol & Toxicol, D-35032 Marburg, Germany
[2] Univ Marburg, Fac Pharm, Inst Pharmaceut Chem, D-35032 Marburg, Germany
关键词
cytisine; iron-chelator; hydroxyl radical; Parkinson's disease; S-PBN; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
D O I
10.1016/S0014-2999(98)00696-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The potential new iron-chelator cytisine and the radical scavenger N-tert-butyl-alpha-(2-sulfophenyl) nitrone (S-PBN) were incubated in a Fenton system and hydroxyl radical formation was measured with the salicylate trapping assay. Both cytisine and S-PBN reduced hydroxyl radical formation in a concentration-dependent manner. For in vivo studies, C57BL/6 mice were injected repeatedly with cytisine (0.5 mg/kg or 2.0 mg/kg s.c.) or saline seven days before and after a single 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injection (30 mg/kg s.c.). Seven days after MPTP treatment alone dopamine levels were significantly reduced to 12% of the control values (p < 0.001), whereas MPTP + cytisine treatment (2 mg/kg) led to more than twofold higher dopamine levels (p < 0.01) compared with MPTP alone. We have shown fbr the first time that cytisine attenuates hydroxyl radical formation in vitro and reduces MPTP-induced dopamine depletion. Thus, cytisine may be useful for the treatment of Parkinson's Disease where the chelation of iron ions could prevent neuronal cell death. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:155 / 163
页数:9
相关论文
共 29 条
  • [21] OLANOW CW, 1996, NEUROS PER, P55
  • [22] BEHAVIORAL AND PHARMACOKINETIC STUDIES ON NICOTINE, CYTISINE AND LOBELINE
    REAVILL, C
    WALTHER, B
    STOLERMAN, IP
    TESTA, B
    [J]. NEUROPHARMACOLOGY, 1990, 29 (07) : 619 - 624
  • [23] TRANSITION-METALS, FERRITIN, GLUTATHIONE, AND ASCORBIC-ACID IN PARKINSONIAN BRAINS
    RIEDERER, P
    SOFIC, E
    RAUSCH, WD
    SCHMIDT, B
    REYNOLDS, GP
    JELLINGER, K
    YOUDIM, MBH
    [J]. JOURNAL OF NEUROCHEMISTRY, 1989, 52 (02) : 515 - 520
  • [24] Santiago M, 1997, J NEUROCHEM, V68, P732
  • [25] INFUSION OF IRON INTO THE RAT SUBSTANTIA-NIGRA - NIGRAL PATHOLOGY AND DOSE-DEPENDENT LOSS OF STRIATAL DOPAMINERGIC MARKERS
    SENGSTOCK, GJ
    OLANOW, CW
    MENZIES, RA
    DUNN, AJ
    ARENDASH, GW
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 1993, 35 (01) : 67 - 82
  • [26] SELECTIVE INCREASE OF IRON IN SUBSTANTIA-NIGRA ZONA COMPACTA OF PARKINSONIAN BRAINS
    SOFIC, E
    PAULUS, W
    JELLINGER, K
    RIEDERER, P
    YOUDIM, MBH
    [J]. JOURNAL OF NEUROCHEMISTRY, 1991, 56 (03) : 978 - 982
  • [27] TEMLETT JA, 1994, J NEUROCHEM, V62, P134
  • [28] INTRANIGRAL INJECTED IRON PROGRESSIVELY REDUCES STRIATAL DOPAMINE METABOLISM
    WESEMANN, W
    BLASCHKE, S
    SOLBACH, M
    GROTE, C
    CLEMENT, HW
    RIEDERER, P
    [J]. JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1994, 8 (03) : 209 - 214
  • [29] THE POSSIBLE ROLE OF IRON IN THE ETIOPATHOLOGY OF PARKINSONS-DISEASE
    YOUDIM, MBH
    BENSHACHAR, D
    RIEDERER, P
    [J]. MOVEMENT DISORDERS, 1993, 8 (01) : 1 - 12